Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | MASTERKEY-232: T-VEC not the way forward in relapsed head and neck cancer

Kevin Harrington • 1 Jun 2018
ASCO 2018
Head and Neck Cancer Pembrolizumab Talimogene laherparepvec
MASTERKEY-232

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, presented data from the Phase Ib MASTERKEY-232 trial (NCT02626000) at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. This study combined oncolytic virus therapy talimogene laherparepvec (T-VEC) with anti-PD-1 monoclonal antibody pembrolizumab in an attempt to enhance the anti-tumor immune response in relapsed metastatic head and neck cancer. While safety data for this trial were adequate, the response rate of 16.7% was too similar to the standard of care, pembrolizumab monotherapy, to justify continuation to Phase III.

More from Kevin Harrington

Novel cell-death targets to enhance chemoradiation in head and neck cancer
2:21
Novel cell-death targets to enhance chemoradiation in head and neck cancer
Kevin Harrington • 20 Oct 2025
Head and neck cancer at ESMO 2025: OrigAMI-4, ASPEN-04, and CompARE
2:59
Head and neck cancer at ESMO 2025: OrigAMI-4, ASPEN-04, and CompARE
Kevin Harrington • 20 Oct 2025
ASPEN-03: evorpacept & pembrolizumab in unresectable, PD-L1+ R/M HNSCC
2:08
ASPEN-03: evorpacept & pembrolizumab in unresectable, PD-L1+ R/M HNSCC
Kevin Harrington • 20 Oct 2025
ASPEN-04: evorpacept with pembrolizumab & chemotherapy in R/M HNSCC
3:04
ASPEN-04: evorpacept with pembrolizumab & chemotherapy in R/M HNSCC
Kevin Harrington • 20 Oct 2025

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals